Informacje o członku
Dr Marta Morales Ballús
Hiszpania
Zespół
Dr Jaume Català Mora
Hiszpania
Dr Elisa Carreras
Hiszpania
Dr Itziar Alonso
Hiszpania
Dr Isabel Ayet
Hiszpania
Dr Ester Casas
Hiszpania
Optometrist Ana Díaz
Hiszpania
Dr Jesús Díaz
Hiszpania
Optometrist Enric Puigventos
Hiszpania
Optometrist Carles Fresno
Hiszpania
Dr Carmen García Vicuña
Hiszpania
Dr Hugo Gonzalez
Hiszpania
Optometrist Enrique Jimenez
Hiszpania
Dr Ana Llorca
Hiszpania
Dr Antonio Federico Martinez Monstseny
Hiszpania
Dr Joan Prat
Hiszpania
Dr Gemma Romeu
Hiszpania
Dr Alicia Serra
Hiszpania
Optometrist Simone Suh
Hiszpania
Dr Mariona Vidal
Hiszpania
Optometrist Begoña Yeste
Hiszpania
Dr Núria Planas
Hiszpania
Centrum HCP
skontaktuj się
Hospital Sant Joan de Déu, Spain
Badania kliniczne
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participants with PMM2-CDG
A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aquaporin-4 antibody Positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD)
A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
A Phase 3, multicenter, randomized, evaluator-blinded clinical trial to assess the safety and efficacy of Clobetasol propionate ophthalmic nanoemulsion, 0.05% compared to Prednisolone acetate, 1% in the treatment of inflammation after cataract surgery in pediatric population 0 to 3 years of age (CLOSE-3)”. CLOBOF3-17IA03 (CLOSE-3).
MyopiaX Treatment for the Reduction of Myopia Progression in Children and Adolescents: Safety and Efficacy Investigation